AG Hudecek

    Michael Hudecek: CAR T-cell Engineering

    Research Hudecek Lab


    We are developing novel personalized immune-based cancer treatments that involve reprogramming of the patient’s own immune system cells which are then used to target and destroy cancer cells.


    We are equipping T cells (white blood cells) with a biosensor (chimeric antigen receptor, CAR) to help them detect and eliminate cancer cells.

    Recent Publications

    Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I (2021)
    Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.
    Cancers; 13(24):6157. Go to publication

    Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M et al. (2021)
    Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). 
    Ann Oncol; S0923-7534(21)04876-6. Go to publication

    Luu, M, Visekruna, A (2021)
    Microbial metabolites: novel therapeutic tools for boosting cancer therapies.
    Trends in Cell Biology, Volume 31, Issue 11. Go to publication

    Jetani, H, Navarro-Bailón, A, Maucheret, M et al. (2021)
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood 2021. Go to publication

    Luu, M, Riester, Z, Baldrich, A et al. (2021)
    Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer.
    Nat Commun 12, 4077. Go to publication